Form 4: Lifecore Biomedical Director Acquires 30,000 Shares of Common Stock

Raymond H. Diradoorian, a director of Lifecore Biomedical, acquired 30,000 shares of common stock on July 8, 2024.

Summary

• On July 8, 2024, Raymond H. Diradoorian, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• The transaction was reported on a Form 4 filing with the SEC.
• Following the transaction, Diradoorian directly owns 69,978 shares of Lifecore Biomedical, Inc.
• The acquisition involved restricted stock units that convert into common stock on a 1-for-1 basis.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director acquiring shares, which can be seen as a slightly positive signal, but it's not a major event.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is contingent upon the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates